Alvotech’s Partner Fuji Pharma Report Submission of Application to MHLW for Approval of First Biosimilar Candidate in Japan
Shots:
- Alvotech commercialization partner Fuji Pharma submitted an application to MHLW for marketing approval of the first biosimilar candidate developed under an exclusive collaboration
- In Nov 2018, the companies collaborated for the commercialization of Alvotech’s biosimilar portfolio in Japan & has expanded its partnerships for an additional biosimilar candidate in Japan in Dec 2020 and Feb 2022 to cover 6 proposed biosimilars in Japan
- In Feb 2022, Fuji get exclusive commercial rights to an undisclosed biosimilar that is currently in early phase development while Alvotech will receive an upfront & will be eligible for milestones tied to development progression & share of the in-market sales
Ref: Globenewswire | Image: Alvotech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
